Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases

Sara Rolandsson Enes, Anna D. Krasnodembskaya, Karen English, Claudia C. Dos Santos, Daniel J. Weiss*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

56 Downloads (Pure)

Abstract

Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases
Original languageEnglish
Article number647652
Number of pages8
JournalFrontiers in Pharmacology
Volume12
DOIs
Publication statusPublished - 19 Apr 2021

Fingerprint

Dive into the research topics of 'Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases'. Together they form a unique fingerprint.

Cite this